PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update
Affirms plans to launch first Acuitas® Rapid Test in first half of 2018 Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) reports financial and operational results for the three and six months ended June 30, 2017 ,
View HTML
Toggle Summary OpGen Announces Date of Second Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its second quarter 2017 financial results after close of market on Tuesday, August 8, 2017 . OpGen’s management team will host a live conference call and webcast at 4:30 p.m.
View HTML
Toggle Summary OpGen Announces Closing of $10 Million Public Offering
GAITHERSBURG, Md. , July 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million .
View HTML
Toggle Summary OpGen Announces Pricing of $10.0 Million Public Offering
GAITHERSBURG, Md. , July 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the pricing of a public offering of an aggregate of 25,000,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common
View HTML
Toggle Summary OpGen Acuitas® MDRO Gene Test Approved by NY State Department of Health
GAITHERSBURG, Md. , July 12, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the New York State Department of Health (NYSDOH) has approved the Acuitas® MDRO Gene Test for use by physicians and healthcare providers in the state. The approval of OpGen’s CLIA laboratory to
View HTML
Toggle Summary OpGen Signs Supply Agreement to Use Thermo Fisher Scientific’s Technology to Advance Acuitas® Rapid Test
GAITHERSBURG, Md. , June 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat
View HTML
Toggle Summary OpGen’s Acuitas® Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Facilities
Results of over 1,000 patient samples for antibiotic resistant bacteria published today in Infection Control & Hospital Epidemiology GAITHERSBURG, Md. , June 15, 2017 (GLOBE NEWSWIRE) -- OpGen , Inc. (NASDAQ:OPGN) today announced the publication of a citywide evaluation of Washington , D.C.’s
View HTML
Toggle Summary OpGen Data at ASM Microbe 2017 Demonstrates Potential of Acuitas Products for Predicting Antibiotic Susceptibility and Infection Control
GAITHERSBURG, Md. , June 05, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the results from additional studies supporting the capabilities of its Acuitas Rapid Test and Acuitas Whole Genome Sequence Analysis to accurately predict antibiotic resistance and for infection control.
View HTML
Toggle Summary OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
GAITHERSBURG, Md. , May 30, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2 nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of rapid diagnostics to combat multi-drug resistant infections.
View HTML
Toggle Summary OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017
GAITHERSBURG, Md. , May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas ® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA .
View HTML